{"success":true,"data":{"pressRelease":{"id":"104069","rtpr_id":"nBwyzqzCa","ticker":"APGE","exchange":"NASDAQ","all_tickers":["APGE"],"title":"Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE","author":"Business Wire","published_at":"2026-07-30T16:07:00.107Z","article_body":"Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates\nAdequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. -\nAPGE\n\nFormer Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law\nfirm of Kahn Swick & Foti\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ksfcounsel.com%2F&esheet=54580310&newsitemid=20260730054376&lan=en-US&anchor=Kahn+Swick+%26amp%3B+Foti&index=1&md5=1dec8628ccf76316ea108419c3ae4709)\n, LLC (“KSF”) are investigating the proposed sale of Apogee Therapeutics\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgm-apge%2F&esheet=54580310&newsitemid=20260730054376&lan=en-US&anchor=Apogee+Therapeutics&index=2&md5=1c779b9f7c4b71d77d96f06572cb58a6)\n, Inc. (NasdaqGM: APGE) to AbbVie (NYSE: ABBV). Under the terms of the\nproposed transaction, shareholders of Apogee will receive $135.11 in cash for\neach share of Apogee that they own. KSF is seeking to determine whether this\nconsideration and the process that led to it are adequate, or whether the\nconsideration undervalues the Company.\n\nIf you believe that this transaction undervalues the Company and/or if you\nwould like to discuss your legal rights regarding the proposed sale, you may,\nwithout obligation or cost to you, e-mail or call KSF Managing Partner Lewis\nS. Kahn (lewis.kahn@ksfcounsel.com (mailto:lewis.kahn@ksfcounsel.com) ) toll\nfree at any time at 833-538-3612, or visit\nhttps://www.ksfcounsel.com/cases/nasdaqgm-apge/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgm-apge%2F&esheet=54580310&newsitemid=20260730054376&lan=en-US&anchor=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgm-apge%2F&index=3&md5=c228a2da4ade307ba2690442d44b7f8a)\nto learn more.\n\nTo learn more about KSF, whose partners include the Former Louisiana Attorney\nGeneral, visit www.ksfcounsel.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ksfcounsel.com&esheet=54580310&newsitemid=20260730054376&lan=en-US&anchor=www.ksfcounsel.com&index=4&md5=a2b505185e24d06d598ec09d77629686)\n.\n\nCONNECT WITH US: Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2Fprofile.php%3Fid%3D61575733915628&esheet=54580310&newsitemid=20260730054376&lan=en-US&anchor=Facebook&index=5&md5=ef565d91c7622577f56408e9581ec41f)\n|| Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fkahn_swick_and_foti%2F&esheet=54580310&newsitemid=20260730054376&lan=en-US&anchor=Instagram&index=6&md5=571f2f5c90b4dc26435bc014896b9a9a)\n|| YouTube\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2F%40kahnswickandfoti&esheet=54580310&newsitemid=20260730054376&lan=en-US&anchor=YouTube&index=7&md5=0710fd0b1accb819b251537d5462592a)\n|| TikTok\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.tiktok.com%2F%40kahn.swick.foti&esheet=54580310&newsitemid=20260730054376&lan=en-US&anchor=TikTok&index=8&md5=ee799853fa8ba22ea6dd0e75fba00f70)\n|| LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fksfcounsel&esheet=54580310&newsitemid=20260730054376&lan=en-US&anchor=LinkedIn&index=9&md5=78ecd177f95bf1983e3643cc861ee498)\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260730054376/en/\n(https://www.businesswire.com/news/home/20260730054376/en/)\n\nKahn Swick & Foti, LLC\n\n1100 Poydras St., Suite 960\n\nNew Orleans, LA 70163\n\nLewis S. Kahn\n\nManaging Partner\n\nlewis.kahn@ksfcounsel.com \n(mailto:lewis.kahn@ksfcounsel.com) \n(833) 538-3612\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBwyzqzCa","title":"Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE","author":"Business Wire","ticker":"APGE","created":"2026-07-30T16:07:00.107Z","tickers":["APGE"],"exchange":"NASDAQ","article_body":"Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates\nAdequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. -\nAPGE\n\nFormer Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law\nfirm of Kahn Swick & Foti\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ksfcounsel.com%2F&esheet=54580310&newsitemid=20260730054376&lan=en-US&anchor=Kahn+Swick+%26amp%3B+Foti&index=1&md5=1dec8628ccf76316ea108419c3ae4709)\n, LLC (“KSF”) are investigating the proposed sale of Apogee Therapeutics\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgm-apge%2F&esheet=54580310&newsitemid=20260730054376&lan=en-US&anchor=Apogee+Therapeutics&index=2&md5=1c779b9f7c4b71d77d96f06572cb58a6)\n, Inc. (NasdaqGM: APGE) to AbbVie (NYSE: ABBV). Under the terms of the\nproposed transaction, shareholders of Apogee will receive $135.11 in cash for\neach share of Apogee that they own. KSF is seeking to determine whether this\nconsideration and the process that led to it are adequate, or whether the\nconsideration undervalues the Company.\n\nIf you believe that this transaction undervalues the Company and/or if you\nwould like to discuss your legal rights regarding the proposed sale, you may,\nwithout obligation or cost to you, e-mail or call KSF Managing Partner Lewis\nS. Kahn (lewis.kahn@ksfcounsel.com (mailto:lewis.kahn@ksfcounsel.com) ) toll\nfree at any time at 833-538-3612, or visit\nhttps://www.ksfcounsel.com/cases/nasdaqgm-apge/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgm-apge%2F&esheet=54580310&newsitemid=20260730054376&lan=en-US&anchor=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgm-apge%2F&index=3&md5=c228a2da4ade307ba2690442d44b7f8a)\nto learn more.\n\nTo learn more about KSF, whose partners include the Former Louisiana Attorney\nGeneral, visit www.ksfcounsel.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ksfcounsel.com&esheet=54580310&newsitemid=20260730054376&lan=en-US&anchor=www.ksfcounsel.com&index=4&md5=a2b505185e24d06d598ec09d77629686)\n.\n\nCONNECT WITH US: Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2Fprofile.php%3Fid%3D61575733915628&esheet=54580310&newsitemid=20260730054376&lan=en-US&anchor=Facebook&index=5&md5=ef565d91c7622577f56408e9581ec41f)\n|| Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fkahn_swick_and_foti%2F&esheet=54580310&newsitemid=20260730054376&lan=en-US&anchor=Instagram&index=6&md5=571f2f5c90b4dc26435bc014896b9a9a)\n|| YouTube\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2F%40kahnswickandfoti&esheet=54580310&newsitemid=20260730054376&lan=en-US&anchor=YouTube&index=7&md5=0710fd0b1accb819b251537d5462592a)\n|| TikTok\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.tiktok.com%2F%40kahn.swick.foti&esheet=54580310&newsitemid=20260730054376&lan=en-US&anchor=TikTok&index=8&md5=ee799853fa8ba22ea6dd0e75fba00f70)\n|| LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fksfcounsel&esheet=54580310&newsitemid=20260730054376&lan=en-US&anchor=LinkedIn&index=9&md5=78ecd177f95bf1983e3643cc861ee498)\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260730054376/en/\n(https://www.businesswire.com/news/home/20260730054376/en/)\n\nKahn Swick & Foti, LLC\n\n1100 Poydras St., Suite 960\n\nNew Orleans, LA 70163\n\nLewis S. Kahn\n\nManaging Partner\n\nlewis.kahn@ksfcounsel.com \n(mailto:lewis.kahn@ksfcounsel.com) \n(833) 538-3612\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-07-30T16:07:00.196276458Z","server_sent_at_ms":1785427620196},"received_at":"2026-07-30T16:07:00.247Z","source_url":"https://www.businesswire.com/news/home/20260730054376/en/"},"analysis":{"id":"93084","press_release_id":"104069","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Kahn Swick & Foti, LLC is investigating the proposed sale of Apogee Therapeutics to AbbVie for $135.11 in cash per share.\n\nThe firm is seeking to determine whether the consideration and the process that led to the deal are adequate or if the company is being undervalued.\n\nInvestors are encouraged to contact the firm without obligation to discuss their legal rights regarding the transaction.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"acquisition_price_per_share":"$135.11"}},"quotedText":"KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.","namedEntities":{"people":[{"name":"Charles C. Foti, Jr., Esq.","role":"Former Attorney General of Louisiana"},{"name":"Lewis S. Kahn","role":"Managing Partner"}],"products":[],"companies":[{"name":"Kahn Swick & Foti, LLC","relationship":"plaintiff law firm"},{"name":"Apogee Therapeutics, Inc.","ticker":"APGE","relationship":"target"},{"name":"AbbVie","ticker":"ABBV","relationship":"acquirer"}],"dollarAmounts":[{"amount":"$135.11","context":"cash per share in proposed sale"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Kahn Swick & Foti. No new disclosure from the issuer; no certified class, no settlement. Routine investigation notice regarding an announced M&A transaction."},"tickerRelevance":{"others":[{"ticker":"ABBV","relevance":"acquirer"}],"primary":"APGE"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Kahn Swick & Foti, LLC is investigating the proposed sale of Apogee Therapeutics to AbbVie for $135.11 in cash per share.\n\nThe firm is seeking to determine whether the consideration and the process that led to the deal are adequate or if the company is being undervalued.\n\nInvestors are encouraged to contact the firm without obligation to discuss their legal rights regarding the transaction.","key_figures":{"customDimensions":{"acquisition_price_per_share":"$135.11"}},"named_entities":{"people":[{"name":"Charles C. Foti, Jr., Esq.","role":"Former Attorney General of Louisiana"},{"name":"Lewis S. Kahn","role":"Managing Partner"}],"products":[],"companies":[{"name":"Kahn Swick & Foti, LLC","relationship":"plaintiff law firm"},{"name":"Apogee Therapeutics, Inc.","ticker":"APGE","relationship":"target"},{"name":"AbbVie","ticker":"ABBV","relationship":"acquirer"}],"dollarAmounts":[{"amount":"$135.11","context":"cash per share in proposed sale"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-30T21:31:35.159Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":278580,"modelName":"glm-4.7"}}